Table 3.

Treatments’ characteristics and toxicities

Treatment	N(%)
EBRT technique:
3D-RT	3 (27.3%)
IMRT	8 (72.7%)
CTV1 (T + anal canal) dose	51 Gy (range: 44-58.5 Gy)
Concomitant CT:
MMC + 5-FU	9 (81.8%)
5-FU i.c. alone	1 (9.1%)
No CT	1 (9.1%)
Residual after EBRT at 4-6 weeks	8 (72.7%)
Time for residual negativity after BT median	2.5 months (range 2-4 months)
Fraction dose BT median	4 Gy (range: 3.5-7 Gy)
Number of fractions:
Single fraction	9 (81.8%)
2 fraction in the same day	1 (9.1%)
2 fraction in different days	1 (9.1%)
ERT-BT split median	63 days (ranging from 22 to 128 days)
OTT mean (overall treat-ment time until end ERT)	36 days (ranging from 31 to 59 days)
OTTB mean (overall treat-ment time until end BT)	95 days (ranging from 59 to 165 days)
Acute toxicities:
Gastrointestinal	3 (3 grade I) (27.3%)
Hematologic	0
Cutaneous	0
Genitourinary	0
Late toxicities:
Gastrointestinal	3 (2 grade I; 1 grade II) (27.3%)
Hematologic	0
Cutaneous	0
Genitourinary	0

EBRT – external beam radiotherapy, 3D-RT – 3D conformal radiotherapy, IMRT – intensity modulated radiotherapy, CTV – clinical target volume, ERT – external radiation therapy, Concomitant CT – concomitant chemotherapy, MMC – mitomycin C, 5-FU – 5-fluorouracil, BT – brachytherapy, OTT – overall treatment time, OTTB – overall treatment time until end BT